At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Pre-Mkt 01-20 09:01:27 EST
330.41
+0.38
+0.12%
盘前328.14
-2.27-0.69%
08:59 EST
High333.03Low326.90Vol4.03M
Open328.70D1 Closing330.03Amplitude1.86%
Mkt Cap177.92BTradable Cap177.43BTotal Shares538.48M
T/O1.33BT/O Rate0.75%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing -- Barrons.com
Dow Jones  ·  01-16
Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing -- Barrons.com
Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide
TIPRANKS  ·  01-16
Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next
TIPRANKS  ·  01-16
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
Reuters  ·  01-15
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress
Reuters  ·  01-15
CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Benzinga_recent_news  ·  01-15
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Weight-Loss Drugs Enter Era of "Long-Term Maintenance + Low-Frequency Injections"; Amgen's (AMGN.US) "Monthly" Advantage Leads $100 Billion Market
Stock News  ·  01-14
Weight-Loss Drugs Enter Era of "Long-Term Maintenance + Low-Frequency Injections"; Amgen's (AMGN.US) "Monthly" Advantage Leads $100 Billion Market
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman
Benzinga_recent_news  ·  01-14
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
Reuters  ·  01-13
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
ADVISORY-Alert incorrectly tagged to Rubicon Organics withdrawn
Reuters  ·  01-13
ADVISORY-Alert incorrectly tagged to Rubicon Organics withdrawn
BRIEF-RO: ANNOUNCES RESEARCH COLLABORATION WITH AMGEN TO EVALUATE REAL-WORLD GLP-1 COVERAGE
Reuters  ·  01-13
BRIEF-RO: ANNOUNCES RESEARCH COLLABORATION WITH AMGEN TO EVALUATE REAL-WORLD GLP-1 COVERAGE
Ro: Announces Research Collaboration With Amgen to Evaluate Real-World Glp-1 Coverage
THOMSON REUTERS  ·  01-13
Ro: Announces Research Collaboration With Amgen to Evaluate Real-World Glp-1 Coverage
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Reuters  ·  01-13
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Scotiabank Keeps Their Buy Rating on Amgen (AMGN)
TIPRANKS  ·  01-13
Scotiabank Keeps Their Buy Rating on Amgen (AMGN)
BUZZ-Street View: Late-stage data awaited to gauge Amgen's weight-loss drug
Reuters  ·  01-13
BUZZ-Street View: Late-stage data awaited to gauge Amgen's weight-loss drug
Citi Sticks to Its Hold Rating for Amgen (AMGN)
TIPRANKS  ·  01-13
Citi Sticks to Its Hold Rating for Amgen (AMGN)
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight
Reuters  ·  01-13
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight
Amgen Highlights Pipeline Advances and Growth Across Oncology, Rare Disease, Inflammation, and General Medicine in New Presentation
Reuters  ·  01-13
Amgen Highlights Pipeline Advances and Growth Across Oncology, Rare Disease, Inflammation, and General Medicine in New Presentation
Amgen: Second Year of Maritide Treatment Very Well Tolerated Including at Quarterly Doses, With Very Low Incidence of Nausea, Vomiting & No New Safety Signals Observed
THOMSON REUTERS  ·  01-13
Amgen: Second Year of Maritide Treatment Very Well Tolerated Including at Quarterly Doses, With Very Low Incidence of Nausea, Vomiting & No New Safety Signals Observed
Amgen: "Large Majority" of People in 52-Week Maritide Extension Study Given Lower Monthly Dose or Quarterly Dose of Drug Maintained Weight Loss Achieved in Part 1 of Phase 2 Trial
THOMSON REUTERS  ·  01-13
Amgen: "Large Majority" of People in 52-Week Maritide Extension Study Given Lower Monthly Dose or Quarterly Dose of Drug Maintained Weight Loss Achieved in Part 1 of Phase 2 Trial

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--